• Yuki Katoh, Hiroyuki Hara, Tomonori Harada, and Shuichi Hirai.
• Division of Anatomical Science, Department of Functional Morphology, Nihon University School of Medicine, Itabashi-ku, TokyoJapan.
• Medicine (Baltimore). 2022 Sep 2; 101 (35): e30471e30471.

AbstractEarly diagnosis of malignant melanoma is critical for effective treatment and reduced patient mortality. However, current clinical and histological variables show limited accuracy in diagnosis. Serum or urine level of 5-S-cysteinyldopa (5-S-CD) is a commonly used melanoma biomarker in Japan owing to its increased sensitivity compared with other melanoma markers. However, its use as a diagnostic marker has shown some limitations. Therefore, here we examined the combination of 5-S-CD with melanoma inhibitory activity, which showed sensitivity in detecting melanoma comparable with that of 5-S-CD, and interleukin-8, a cytokine linked with melanoma progression, in a cohort of Japanese patients with melanoma. Our results revealed that the triple combination of 5-S-CD, melanoma inhibitory activity, and interleukin-8 showed high diagnostic accuracy in detecting melanoma compared with each of the individual factors. Importantly, the triple marker showed specificity and utility in detecting early-stage melanoma. Our results suggest the utility of the triple marker as a diagnostic biomarker for melanoma patients.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

11 keywords...

hide…